Amundi’s Ginkgo Bioworks DNA Stock Holding History

Amundi’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-8,179	Closed	-$302K	–	1947
2024 Q1	$302K	Buy	8,179 +663	+9%	+$34.3K	﹤0.01%	1541
2023 Q4	$454K	Buy	7,516 +1,659	+28%	+$102K	﹤0.01%	1452
2023 Q3	$389K	Buy	5,857 +1,093	+23%	+$87.4K	﹤0.01%	1452
2023 Q2	$339K	Hold	4,764	–	–	﹤0.01%	1472
2023 Q1	$234K	Buy	4,764 +460	+11%	+$29.1K	﹤0.01%	1526
2022 Q4	$293K	Buy	+4,304	New	+$396K	﹤0.01%	1470
2022 Q3	–	Sell	-2,987	Closed	-$369K	–	1855
2022 Q2	$369K	Buy	2,987 +1,512	+103%	+$184K	﹤0.01%	1303
2022 Q1	$201K	Buy	1,475 +1,113	+307%	+$217K	﹤0.01%	1388
2021 Q4	$89K	Hold	362	–	–	﹤0.01%	1578
2021 Q3	$168K	Buy	+362	New	+$176K	﹤0.01%	1457

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Amundi's DNA Position: Q2 2024 in Review

Amundi sold out of Ginkgo Bioworks (DNA) in Q2 2024, closing a stake of 8,179 shares — an estimated $302K sold.

Amundi first reported a position in DNA in Q3 2021 and held it in 10 quarters. The position peaked at $454K in Q4 2023. 313 funds tracked by Wall St. Rank hold DNA as of Q2 2024.

Amundi reported no remaining Ginkgo Bioworks position as of Q2 2024 after selling out during the quarter.
Amundi sold 8,179 Ginkgo Bioworks shares in Q2 2024, an estimated $302K.
Amundi first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 10 quarters.
Amundi's Ginkgo Bioworks position peaked at $454K in Q4 2023.
313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2024.

Based on Amundi's 13F filing for Q2 2024, filed 14 Aug 2024.